BRCA in breast cancer: ESMO clinical practice guidelines

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Balmana J ^a   Diez, O ^a,b   Rubio, I ^a   Castiglione, M ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; OLAPARIB; PLATINUM COMPLEX; TAMOXIFEN; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MASTECTOMY; OVARY CANCER; PATIENT REFERRAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DISEASE SUSCEPTIBILITY; EUROPE; FEMALE; GENETIC TESTING; HETEROZYGOTE; HUMANS; MALE; MAMMOGRAPHY; MASTECTOMY; MUTATION, MISSENSE; OVARIECTOMY; PENETRANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 77954326667     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq161     Document Type: Article

References (18)

1. Fackental JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-948.
2. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Pharoah PD, Antoniou A, Easton D, Ponder B. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803.
4. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
5. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379-1388.
6. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast cancer screening in women with familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
7. Gronwald J, Tung N, Foulkes WD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118: 2281-2284.
8. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
9. Gerber B, Krause A, Dieterich M et al. The oncologic safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009; 249: 461-468.
10. Boughey JC, Khakpour N, Meric-Bernstam F et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 2006; 107: 1440-1447.
11. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
12. Andrieu N, Goldgar D, Easton D et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006; 98: 535-544.
13. Domcheck SM, Friebel TM, Neuhausen SL et al. Mortality after bilateral salpingooophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-229.
14. Kauff N, Domcheck SM, Friebel TM et al. Risk reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynaecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337.
15. Domcheck SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006; 25: 5825-5831.
16. Robson M, Offit K. Management of an inherited predisposition to breast cancer. N Engl J Med 2007; 357: 154-162.
17. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
18. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008; 1138: 136-145.